This Article Full Text Full Text (PDF) Correction (v103,p2422) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zipes, D. P. Search for Related Content PubMed PubMed Citation Articles by Zipes, D. P. Related Collections Other Treatment Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2001;103:1372.)
© 2001 American Heart Association, Inc.

Editorials

Implantable Cardioverter-Defibrillator: A Volkswagen or a Rolls Royce

How Much Will We Pay To Save A Life?

Douglas P. Zipes, MD

From the Krannert Institute of Cardiology, Indiana University School of Medicine and the Roudebush Veterans Administration Medical Center, Indianapolis, Ind.

Correspondence to Douglas P. Zipes, MD, Krannert Institute of Cardiology, 1111 W. 10th Street, Indianapolis, IN 46202-4800. E-mail dzipes@iupui.edu

Key Words: Editorials • arrhythmia • defibrillation

A 45-year-old man with end-stage cardiomyopathy died while waiting for a heart transplant after living almost 1 year in a coronary care unit supported by intravenous medications. Around the time of his death, an off-duty police officer in a neighboring town watching a high school football game saw one of the player’s fathers slump forward unconscious. The officer ran to his patrol car, grabbed the automated external defibrillator he had recently been assigned, and defibrillated the father’s ventricular fibrillation. The man immediately regained consciousness and protested being taken to the hospital because he wanted to watch his son finish the game! These extremes provide dramatic bookends to the spectrum of how we spend money to save a life. Some therapies are inexpensive and others are not, and society has to make difficult choices about how to use our limited resources.

The implantable cardioverter-defibrillator (ICD) represents one of the most important advances in the past 50 years in the treatment of patients with life-threatening ventricular tachyarrhythmias.¹ Five pivotal prospective, randomized, clinical trials have helped define its use. In 3 secondary prevention trials, Antiarrhythmics Versus Implantable Defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Survival Hamburg (CASH),² and 2 primary prevention trials, Multicenter Automatic Defibrillator Implantation Trial (MADIT)³ and Multicenter Unsustained Tachycardia Trial (MUSTT),⁴ the ICD was superior to antiarrhythmic drugs (mostly or exclusively amiodarone) in reducing mortality in patients with life-threatening ventricular tachyarrhythmias. Further analysis of data from the 3 secondary prevention trials established that the ICD did not . . . [Full Text of this Article]

This article has been cited by other articles:

				A. F. Hernandez, G. C. Fonarow, L. Liang, S. M. Al-Khatib, L. H. Curtis, K. A. LaBresh, C. W. Yancy, N. M. Albert, and E. D. Peterson Sex and Racial Differences in the Use of Implantable Cardioverter-Defibrillators Among Patients Hospitalized With Heart Failure JAMA, October 3, 2007; 298(13): 1525 - 1532. [Abstract] [Full Text] [PDF]

				J. P. DiMarco Implantable Cardioverter-Defibrillators N. Engl. J. Med., November 6, 2003; 349(19): 1836 - 1847. [Full Text] [PDF]

				G. Boriani, M. Biffi, C. Martignani, C. Camanini, F. Grigioni, C. Rapezzi, and A. Branzi Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs Eur J Heart Fail, August 1, 2003; 5(4): 419 - 425. [Abstract] [Full Text] [PDF]

				J. A. Ezekowitz, P. W. Armstrong, and F. A. McAlister Implantable Cardioverter Defibrillators in Primary and Secondary Prevention: A Systematic Review of Randomized, Controlled Trials Ann Intern Med, March 18, 2003; 138(6): 445 - 452. [Abstract] [Full Text] [PDF]

				D.K. Whynes Health care costs ... Eur. Heart J., August 2, 2002; 23(16): 1237 - 1239. [PDF]

				T. H. Makikallio, H. V. Huikuri, M. T. La Rovere, G. D. Pinna, S. H. Hohnloser, F. I. Marcus, A. Mortara, R. Nohara, J. T. Bigger Jr, A. J. Camm, et al. Risks in Risk Stratification: What Is Relevant in Practice? * Response Circulation, March 26, 2002; 105 (12): e69 - e70. [Full Text] [PDF]

				A. Hallstrom and D. P. Zipes Implantable Cardioverter Defibrillator: A Volkswagon or a Rolls Royce: How Much Will You Pay to Save a Life? Circulation, December 11, 2001; 104 (24): e148 - e148. [Full Text] [PDF]

				D. P. Zipes Saving Time Saves Lives Circulation, November 20, 2001; 104(21): 2506 - 2508. [Full Text] [PDF]

				R. Sheldon, B. J. O'Brien, G. Blackhouse, R. Goeree, B. Mitchell, G. Klein, R. S. Roberts, M. Gent, and S. J. Connolly Effect of Clinical Risk Stratification on Cost-Effectiveness of the Implantable Cardioverter-Defibrillator: The Canadian Implantable Defibrillator Study Circulation, October 2, 2001; 104(14): 1622 - 1626. [Abstract] [Full Text] [PDF]

				D. V. Exner, G. J. Klein, and E. N. Prystowsky Primary Prevention of Sudden Death With Implantable Defibrillator Therapy in Patients With Cardiac Disease: Can We Afford to Do It? (Can We Afford Not To?) Circulation, September 25, 2001; 104(13): 1564 - 1570. [Full Text] [PDF]

				ICDs Work, But Can We Afford Them? Journal Watch Cardiology, May 18, 2001; 2001(518): 3 - 3. [Full Text]